The DOI matches its Crossref record.
Neurocysticercosis: Short Course of Treatment With Albendazole
Abstract
Eighteen patients with nonenhancing parenchymal brain cysts were treated with albendazole; 9 patients were treated for 3 days and 9 patients for 1 month at daily doses of 15 mg/kg of body weight. Three months after starting therapy, results showed that in both groups the treatment was highly effective. Control studies carried out in the same group before the trial did not show any significant improvement. Five patients were controls and were treated only with symptomatic drugs. The total diameter of the lesions was reduced from 220.1 mm to 52.1 mm, which signifies a reduction of 76.3% in patients treated for a period of 3 days, and from 278.5 mm to 82.1 mm, which is 70.5%, in patients treated for 30 days. We conclude that albendazole administered according to the 3-day therapeutic scheme proposed above is as highly effective for the treatment of parenchymal brain cysticercosis as the 30-day scheme.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even a shorter course of treatment with albendazole (15 mg/kg daily for 3 days) was as effective as the 30-day course treatment [157]”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [157]
Citations
Cited by
Sorted by citations
Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
Chai, J.-Y., Jung, B.-K., & Hong, S.-J. (2021) · The Korean Journal of Parasitology · doi:10.3347/kjp.2021.59.3.189 · Cited by 286
Metadata
- Authors
- Alarcón, F.
- Affiliations
- Hospital de Especialidades Eugenio Espejo (EC)
- Corresponding author
- Alarcón, Fernando
- ORCID
- Alarcón, Fernando
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 1989-11-01
- Volume
- 46
- Issue
- 11
- Pages
- 1231
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2057635878
- Cited by
- 63
- References
- 0
- Citations by year
- 2025: 1 · 2021: 3 · 2020: 2 · 2017: 3 · 2014: 1 · 2013: 1
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Parasitic infections in humans and animals
- Life Sciences › Immunology and Microbiology › Parasitology › Parasitic Infections and Diagnostics
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Mollusks and Parasites Studies
- Keywords
- neurocysticercosis, albendazole, short-course treatment, treatment duration, antiparasitic treatment
- MeSH terms
- Adolescent, Adult, Aged, Brain Diseases, Cysticercosis, Female, Humans, Male, Middle Aged, Tomography, X-Ray Computed, Albendazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
